New oral drug trial targets dangerous virus in vulnerable cancer patients
NCT ID NCT07014319
Summary
This study is testing whether an oral antiviral drug called maribavir can safely and effectively control cytomegalovirus (CMV) infections in patients with multiple myeloma or lymphoma. These patients are receiving a newer type of cancer treatment (bispecific antibodies) that can weaken the immune system and allow CMV to reactivate. The trial will enroll 20 adults to see if maribavir can reduce the virus levels and prevent serious complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.